EARLY Randomized Clinical Trial: 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes
Key Findings:
An intermittent fasting plan of 2 nonconsecutive fasting days and 5 days of habitual intake per week combined with a meal replacement diet (5:2 MR) showed significant benefits for patients with early type 2 diabetes.
Study Details:
The study was conducted in 9 centers across China and included 509 eligible patients. 405 patients were randomly assigned to 3 groups for the 16-week treatment, with an 8-week follow-up.
Results:
Participants in the 5:2 MR group showed the greatest reduction in hemoglobin A1c (HbA1c) levels, significantly greater than those receiving metformin or empagliflozin. Additionally, the 5:2 MR group experienced greater weight loss compared to the other groups.
Implications:
The trial found that 5:2 MR could improve glycemic outcomes and weight loss in the short term, making it a promising initial intervention and early management for type 2 diabetes.
Value of Clinical Trials:
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.
Streamlining Healthcare Operations:
Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally, enhancing workflows and improving patient outcomes.
Learn More:
Discover how AI can help clinics enhance their workflows and improve patient outcomes at aidevmd.com.
